‘LAUNCHING NEW DIVISION FOR GLAUCOMA THERAPY’

“We’ve already launched our super-specialty ophthalmic surgical division, ‘HyTek’ which caters to hi-tech solutions for ophthalmic surgical needs. In 2022, we are planning more expansion into ophthalmic surgical devices by launching new surgical products and strengthening our surgical devices team. We are also more focused on recruiting new talent (over 100 candidates) who will be part of our Ophthalmic, Dermatology and ENT segments. Apart from that, we’ll be launching a new division dedicated to Glaucoma therapy. To compete in a post-COVID digital world, organisations need to elevate their relationships with customers as partners. Therefore, we are aiming to engage ourselves in patient centric activities and enhance our marketing efforts that’ll revolve around patients. Over the coming years, we’ll also be investing heavily in clinical trials and new drug approvals.”

- NIKKHIL K MASURKAR,

Executive Director, Entod Pharmaceuticals, Mumbai